I-Mab Bio­phar­ma to split US, Chi­na busi­ness­es to cut costs, mit­i­gate po­ten­tial risks

I-Mab Bio­phar­ma may have long tak­en pride in be­ing a Chi­na-based glob­al play­er, but from here on out, it wants to be known as a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.